6 completed, 4 not yet recruiting, 2 recruiting, 2 terminated. 4 Phase 3, 2 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 4.
Follow Ceftazidime-Avibactam: new trials by email Literature Review of Ceftazidime-Avibactam trials Research Report on Ceftazidime-Avibactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam - Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis | Phase 2 | Not yet recruiting | Wockhardt | 279 | 2026-09-30 | 2026-09-24 |
| Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance - Hematologic Neoplasms, Gram-Negative Bacterial Infections | Not yet recruiting | Sizhou Feng | 60 | 2026-07-09 | 2026-07-14 | |
| A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP Meropenem and Pralurbactam, Ceftazidime-avibactam - Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-01-22 | 2026-02-17 |
| Optimising TREATment for Severe Gram-Negative Bacterial Infections Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem - Bloodstream Infection, Ventilator Associated Bacterial Pneumonia | Phase 4 | Recruiting | National University of Singapore | 600 | 2025-04-21 | 2025-06-04 |
| Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. Meropenem Injection, Ceftazidime-avibactam, Teicoplanin - Acute-On-Chronic Liver Failure | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 150 | 2025-02-10 | 2025-02-10 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam - Intra-abdominal Infections | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 786 | 2024-10-31 | 2024-10-09 |
| Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Ceftazidime-avibactam, Colistin - Carbapenem-Resistant Enterobacteriaceae Infection | Phase 3 | Terminated | King Faisal Specialist Hospital & Research Center | 29 | 2022-06-01 | 2024-06-14 |
| Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients Ceftazidime-avibactam - Severe Sepsis, Carbapenem Resistant Bacterial Infection | Completed | First Affiliated Hospital of Zhejiang University | 33 | 2021-06-01 | 2026-09-10 | |
| Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections Ceftazidime-avibactam - Gram Negative Infections | Completed | Pfizer | 189 | 2021-01-29 | 2024-08-14 | |
| Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia Ceftazidime-avibactam - Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia | Phase 1 | Terminated | Pfizer | 4 | 2020-06-15 | 2022-09-09 |
| Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria Ceftazidime-Avibactam, Best Available Therapy - Carbapenem-Resistant Enterobacteriaceae Infection | Completed | Maimónides Biomedical Research Institute of Córdoba | 348 | 2019-10-01 | 2021-07-20 | |
| A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam AZACTAM, Ceftazidime-Avibactam - Bacterial Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2019-07-09 | 2022-06-07 |
| Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis Ceftazidime-avibactam - Renal Failure, Bacterial Infections | Unknown | Temple University | 10 | 2017-03-13 | 2019-04-10 | |
| Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF Ceftazidime-avibactam - Bacterial Infections | Completed | University of Pittsburgh | 20 | 2017-01-01 | 2020-09-29 | |
| Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Ceftazidime-avibactam, metronidazole, Meropenem - Complicated Intra-abdominal Infection | Phase 3 | Completed | Pfizer | 486 | 2013-01-01 | 2017-09-06 |
Bacterial Infections (3) · Critical Illness (2) · Sepsis (2) · Acute-On-Chronic Liver Failure (1) · Gram-Negative Bacterial Infections (1) · Healthcare-Associated Pneumonia (1) · Hematologic Neoplasms (1) · Intraabdominal Infections (1) · Pseudomonas Infections (1) · Renal Insufficiency (1)
Pfizer (3) · Qilu Pharmaceutical Co., Ltd. (2) · First Affiliated Hospital of Zhejiang University (1) · Institute of Liver and Biliary Sciences, India (1) · King Faisal Specialist Hospital & Research Center (1) · Maimónides Biomedical Research Institute of Córdoba (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National University of Singapore (1) · Sizhou Feng (1) · Temple University (1) · University of Pittsburgh (1) · Wockhardt (1)
China (7) · India (3) · United States (3) · Saudi Arabia (2) · Spain (2) · Australia (1) · Lebanon (1) · Malaysia (1) · Qatar (1) · Singapore (1) · South Africa (1) · South Korea (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)
Christina Rose, Pharm.D. (1) · Hakeam Hakeam (1) · Paul A Newell, MBBS, MRCP (1) · Ryan Shields, Pharm D (1) · Sizhou Feng, MD (1) · YongHong Xiao, PhD (1) · Yunfei Ju, MM (1) · Zainab Al Duhailib (1)
PMID 28363526, PMID 29912399, PMID 30061279, PMID 30221827, PMID 32602065, PMID 37700689
2018 (1), 5UM1AI104681-09 (1)